New hope for breast cancer patients: extra drug may wipe out remaining tumor
NCT ID NCT07589699
First seen May 17, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests whether adding 4 cycles of the drug T-DXh can eliminate leftover cancer in women with HER2-positive breast cancer who still have disease after standard chemotherapy. About 59 participants will receive T-DXh before surgery. The goal is to see if more patients can achieve a complete response, meaning no cancer found in breast or lymph nodes after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.